Polydatin reduces cardiotoxicity of tyrosine kinase inhibitor sunitinib by decreasing pro-oxidative stress, pro-inflammatory cytokines and NLRP3 inflammasome expression.
Massimiliano Berretta(University of Messina), Nicola Maurea(Cancer Institute (WIA)), Ernesta Cavalcanti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Raffaele Di Francia(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), R. Taibi, Simona Buccolo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vincenzo Quagliariello(Cancer Institute (WIA)), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Monica Montopoli(University of Padua), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460